Full IPO calendar & reports HERE.
In order of largest IPO first.
(1) Based in New York, NY,Goldman Sachs BDC (GSBD), scheduled a $123 million IPO on the NYSE with a market capitalization of $726 million at a price range midpoint of $11 for the week of March 16, 2015.
GSBD is a specialty finance closed end fund focused on lending to middle-market companies. Goldman Sachs division is the investment manager.
(2) Bridgewater, NJ,Valeritas (VLRX) scheduled a $75 million IPO on Nasdaq with a market capitalization of $240 million at a price range midpoint of $15 for Friday, March 20, 2014.
LVRX is a commercial-stage medical technology company focused on developing innovative technologies to improve the health and quality of life of people with Type 2 diabetes.
VLRX designed its first commercialized product, the V-Go Disposable Insulin Delivery Device, or V-Go, to help patients with Type 2 diabetes who require insulin to achieve and maintain their target blood glucose goals.
(3) Based in Rehovot, Israel,SteadyMed (STDY) scheduled a $56 million IPO on Nasdaq with a market capitalization of $160 million at a price range midpoint of $13 for Friday, March 20, 2015.
STDY is a specialty pharmaceutical company focused on the development and commercialization of therapeutic product candidates that address the limitations of market-leading products in certain orphan and other well-defined, high-margin specialty markets.
The primary focus is to obtain approval for the sale of Trevyent® for the treatment of pulmonary arterial hypertension, or PAH.
(4) Birmingham, AL,National Commerce (NCOM) scheduled a $31 million IPO on Nasdaq with a market capitalization of $177 million at a price range midpoint of $19.50 for the week of March 16, 2015.
NCOM is a bank holding company headquartered in Birmingham, Alabama.
DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of equities.com. Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please go to: http://www.equities.com/disclaimer